Considering the aforementioned effect of both P2X1 and P2X7 antagonists on platelet aggregation, dense-granule secretion, and integrin activation, the role of P2X receptors in platelet activity in the context of EAE should be elucidated by further studies, as they may embody promising targets for future MS therapy. Here, P2RX7 is linked to myeloid sarcoma.